Yunjie Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Yunjie Wang has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Bo Qiu
Department of Neurosurgery, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China
5 shared publications Yong Wang
First Hospital of China Medical University
4 shared publicationsJun Tao
Department of Neurosurgery, First Hospital of China Medical University, No. 155, North Nanjing Street, Heping District, Shenyang, Liaoning, China, 110001
3 shared publicationsJun Wang
Department of Neurosurgery, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China
3 shared publicationsShaowu Ou
First Hospital of China Medical University
2 shared publicationsAlain Biteghe-Bi-Nzeng
Neurosurgery Department of the First Hospital Affiliated to China Medical University, Shenyang, China
1 shared publication
Latest Publications
- 20 February 2016
- Published by Springer Nature in Tumor Biology
- Vol. 37 (8) , 11049-11055
Rab23 is overexpressed in human astrocytoma and promotes cell migration and invasion through regulation of Rac1
Rab23 overexpression has been implicated in several human cancers. However, its biological roles and molecular mechanism in astrocytoma have not been elucidated. The aim of this study is to explore clinical significance and biological roles of Rab23 in astrocytoma. We observed negative Rab23 staining in normal astrocytes and positive staining in 39 out of 86 (45 %) astrocytoma specimens using immunohistochemistry. The positive rate of Rab23 was higher in grades III and IV (56.5 %, 26/46) than grades I + II astrocytomas (32.5 %, 13/40, p < 0.05). Transfection of Rab23 plasmid was performed induced A172 cell proliferation, colony formation, invasion, and migration, while Rab23 depletion with siRNA reduced these abilities of U87 cells. In addition, we found that Rab23 transfection upregulated while its depletion reduced Rac1 activity. Treatment of transfected cells with a Rac1 inhibitor decreased Rac1 activity and invasion. In conclusion, Rab23 serves as an important oncoprotein in human astrocytoma by regulating cell invasion and migration through Rac1 activity.
- 20 February 2016
- Published by Springer Nature in Tumor Biology
- Vol. 37 (8) , 11049-11055
Rab23 is overexpressed in human astrocytoma and promotes cell migration and invasion through regulation of Rac1
Rab23 overexpression has been implicated in several human cancers. However, its biological roles and molecular mechanism in astrocytoma have not been elucidated. The aim of this study is to explore clinical significance and biological roles of Rab23 in astrocytoma. We observed negative Rab23 staining in normal astrocytes and positive staining in 39 out of 86 (45 %) astrocytoma specimens using immunohistochemistry. The positive rate of Rab23 was higher in grades III and IV (56.5 %, 26/46) than grades I + II astrocytomas (32.5 %, 13/40, p < 0.05). Transfection of Rab23 plasmid was performed induced A172 cell proliferation, colony formation, invasion, and migration, while Rab23 depletion with siRNA reduced these abilities of U87 cells. In addition, we found that Rab23 transfection upregulated while its depletion reduced Rac1 activity. Treatment of transfected cells with a Rac1 inhibitor decreased Rac1 activity and invasion. In conclusion, Rab23 serves as an important oncoprotein in human astrocytoma by regulating cell invasion and migration through Rac1 activity.
- Open Access
- 27 January 2015
- Published by Spandidos Publications in Oncology Letters
- Vol. 9 (4) , 1795-1801
Diagnosis and treatment of primary central nervous system lymphoma: A report of nine cases and literature review
Primary central nervous system lymphoma (PCNSL) is a rare, highly malignant tumor type of the nervous system and is associated with poor prognosis. To investigate the efficacy of current treatment strategies for PCNSL, the present study retrospectively analyzed the clinical and pathological features, imaging results, clinical management, and prognoses of nine patients with PCNSL. Postoperative pathological examination confirmed a diagnosis of lymphoma in all the patients and the adopted treatment regimens were as follows: Stereotactic biopsy in combination with methylprednisolone (MP) and methotrexate (MTX) and/or radiotherapy; craniotomy in combination with dexamethasone or MP and/or radiotherapy; and neuroendoscopic surgery in combination with MP and MTX. The follow‑up period was 5‑27 months with an average duration of 10.1 months. After the initial three months of follow‑up, the clinical symptoms of all the patients were significantly improved, with the tumor disappearing in seven patients and evidently reducing in size in two patients. However, six patients exhibited tumor recurrence, three of whom eventually succumbed to the disease during the follow‑up period. Currently, comprehensive treatment strategies based on a combination of stereotactic biopsy, chemotherapy and radiotherapy are recommended for the treatment of PCNSL. However, the effectiveness of these treatments remains unsatisfactory. Thus, future studies are required to investigate methods for improving the efficacy of PCNSL treatment strategies.
- 27 January 2015
- Published by Spandidos Publications in Oncology Letters
- Vol. 9 (4) , 1795-1801
Open AccessDiagnosis and treatment of primary central nervous system lymphoma: A report of nine cases and literature review
Primary central nervous system lymphoma (PCNSL) is a rare, highly malignant tumor type of the nervous system and is associated with poor prognosis. To investigate the efficacy of current treatment strategies for PCNSL, the present study retrospectively analyzed the clinical and pathological features, imaging results, clinical management, and prognoses of nine patients with PCNSL. Postoperative pathological examination confirmed a diagnosis of lymphoma in all the patients and the adopted treatment regimens were as follows: Stereotactic biopsy in combination with methylprednisolone (MP) and methotrexate (MTX) and/or radiotherapy; craniotomy in combination with dexamethasone or MP and/or radiotherapy; and neuroendoscopic surgery in combination with MP and MTX. The follow‑up period was 5‑27 months with an average duration of 10.1 months. After the initial three months of follow‑up, the clinical symptoms of all the patients were significantly improved, with the tumor disappearing in seven patients and evidently reducing in size in two patients. However, six patients exhibited tumor recurrence, three of whom eventually succumbed to the disease during the follow‑up period. Currently, comprehensive treatment strategies based on a combination of stereotactic biopsy, chemotherapy and radiotherapy are recommended for the treatment of PCNSL. However, the effectiveness of these treatments remains unsatisfactory. Thus, future studies are required to investigate methods for improving the efficacy of PCNSL treatment strategies.
- 1 September 2014
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 40 (9) , 1062-1071
Microsurgery for the treatment of primary malignant intracranial melanoma: A surgical series and literature review
- 1 September 2014
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 40 (9) , 1062-1071
Microsurgery for the treatment of primary malignant intracranial melanoma: A surgical series and literature review
- 22 April 2014
- Published by Springer Nature in Acta Neurochirurgica
- Vol. 156 (6) , 1085-1097
Selection of surgical approaches based on semi-quantifying the skull-base invasion by petroclival meningiomas: a review of 66 cases
Petroclival meningiomas are still challenging for neurosurgeons. In the present study, we reviewed 66 petroclival meningiomas that underwent craniotomy to assess the surgical approaches for petroclival meningiomas based on semi-quantifying tumor extension to skull base and to evaluate the outcomes. According to invasion characteristics, skull base related to petroclival meningiomas was semi-quantitatively divided into five regions: upper, middle, and lower petroclival regions (region A, B, and C, respectively), cerebellopontine angle region (region D), and parasellar and cavernous sinus region (region E). Appropriate surgical approaches were adopted for petroclival meningiomas with varying degrees of invasion, including the subtemporal (11/66), retrosigmoid (15/66), presigmoid (32/66), combined retrosigmoid and far-lateral (2/66), supra-infratentorial (4/66), and extended middle cranial fossa (2/66) approaches. The results showed that involvement of region A, B, and C was in 64, 50, and eight patients, respectively. Invasion to region D and E occurred in 13 and 39 cases, respectively. The ratio of single region involvement was only 7.6 %, whereas most petroclival meningiomas tended to invade more regions (39.4 % for two, 37.9 % for three, 12.1 % for four, and 3.0 % for five regions, respectively). Gross total resection was achieved in 29 cases (43.9 %), near total resection in 27 cases (40.9 %), and subtotal resection in ten cases (15.2 %). After a mean follow-up period of 32.21 months, obvious cranial nerve deficits existed in seven patients, and recurrence occurred in eight patients. We introduced a simple and practicable method for classification of petroclival meningiomas, which could semi-quantify tumor invasion and help to select surgical approaches. With careful preoperative evaluation, a cautiously selected approach would improve the prognosis.
- 22 April 2014
- Published by Springer Nature in Acta Neurochirurgica
- Vol. 156 (6) , 1085-1097
Selection of surgical approaches based on semi-quantifying the skull-base invasion by petroclival meningiomas: a review of 66 cases
Petroclival meningiomas are still challenging for neurosurgeons. In the present study, we reviewed 66 petroclival meningiomas that underwent craniotomy to assess the surgical approaches for petroclival meningiomas based on semi-quantifying tumor extension to skull base and to evaluate the outcomes. According to invasion characteristics, skull base related to petroclival meningiomas was semi-quantitatively divided into five regions: upper, middle, and lower petroclival regions (region A, B, and C, respectively), cerebellopontine angle region (region D), and parasellar and cavernous sinus region (region E). Appropriate surgical approaches were adopted for petroclival meningiomas with varying degrees of invasion, including the subtemporal (11/66), retrosigmoid (15/66), presigmoid (32/66), combined retrosigmoid and far-lateral (2/66), supra-infratentorial (4/66), and extended middle cranial fossa (2/66) approaches. The results showed that involvement of region A, B, and C was in 64, 50, and eight patients, respectively. Invasion to region D and E occurred in 13 and 39 cases, respectively. The ratio of single region involvement was only 7.6 %, whereas most petroclival meningiomas tended to invade more regions (39.4 % for two, 37.9 % for three, 12.1 % for four, and 3.0 % for five regions, respectively). Gross total resection was achieved in 29 cases (43.9 %), near total resection in 27 cases (40.9 %), and subtotal resection in ten cases (15.2 %). After a mean follow-up period of 32.21 months, obvious cranial nerve deficits existed in seven patients, and recurrence occurred in eight patients. We introduced a simple and practicable method for classification of petroclival meningiomas, which could semi-quantify tumor invasion and help to select surgical approaches. With careful preoperative evaluation, a cautiously selected approach would improve the prognosis.
- 20 November 2013
- Published by Wolters Kluwer Health in Chinese Medical Journal
- Vol. 126 (22) , 4295-4300
Plasma levels of tissue inhibitor of matrix metalloproteinase-1 correlate with diagnosis and prognosis of glioma patients
Background: There is no validated blood biomarker available for glioma management. Invasive growth is the key feature of glioma. We assessed the clinical usefulness of plasma tissue inhibitor of metalloproteinase 1 (TIMP-1), which has less molecular weight than metalloproteinases, as a potential blood biomarker for glioma. Methods: A total of 285 patients and 59 normal subjects were studied. Plasma concentration of TIMP-1 was measured with enzyme-linked immunosorbent assay. Plasma TIMP-1 was compared between normal and glioma patients, between patients with different pathological grades, and between patients with different prognoses. Longitudinal changes in plasma TIMP-1 during treatment were also evaluated. Plasma matrix metalloproteinase (MMP)-9 level was also assayed and its clinical usefulness was compared with that of TIMP-1. Results: Plasma TIMP-1 and MMP-9 were both increased in glioma patients compared with normal controls (TIMP-1: P P=0.007). Plasma TIMP-1 increases with increased tumor grade. In Grade IV gliomas, plasma TIMP-1 significantly increased after “successful removal” of the tumor (paired samples t-test, before operation vs. during chemotherapy without recurrence, t = -2.131, P=0.038), but did not change significantly at the time of tumor recurrence (during chemotherapy without recurrence vs. after tumor recurrence, t = -0.652, P=0.632). High plasma TIMP-1 level correlated with better survival in Grade IV glioma patients (hazard ratio: 0.550, 95% CI: 0.101-1.000, P=0.036). In Grade IV gliomas, patients with higher plasma TIMP-1 had significantly longer survival time than those with lower plasma TIMP-1 level (25.23 vs. 18.95 months, log-rank P=0.045). Plasma MMP-9 did not show significant association with either the pathological grade or the prognosis of glioma patients. Conclusions: Plasma TIMP-1 is associated with the diagnosis and prognosis of glioma patients. It appears to have better usefulness for guiding clinical decision making than plasma MMP-9. Further studies in an expanded patient population are needed to better define its clinical usefulness.
- 20 November 2013
- Published by Wolters Kluwer Health in Chinese Medical Journal
- Vol. 126 (22) , 4295-4300
Plasma levels of tissue inhibitor of matrix metalloproteinase-1 correlate with diagnosis and prognosis of glioma patients
Background: There is no validated blood biomarker available for glioma management. Invasive growth is the key feature of glioma. We assessed the clinical usefulness of plasma tissue inhibitor of metalloproteinase 1 (TIMP-1), which has less molecular weight than metalloproteinases, as a potential blood biomarker for glioma. Methods: A total of 285 patients and 59 normal subjects were studied. Plasma concentration of TIMP-1 was measured with enzyme-linked immunosorbent assay. Plasma TIMP-1 was compared between normal and glioma patients, between patients with different pathological grades, and between patients with different prognoses. Longitudinal changes in plasma TIMP-1 during treatment were also evaluated. Plasma matrix metalloproteinase (MMP)-9 level was also assayed and its clinical usefulness was compared with that of TIMP-1. Results: Plasma TIMP-1 and MMP-9 were both increased in glioma patients compared with normal controls (TIMP-1: P P=0.007). Plasma TIMP-1 increases with increased tumor grade. In Grade IV gliomas, plasma TIMP-1 significantly increased after “successful removal” of the tumor (paired samples t-test, before operation vs. during chemotherapy without recurrence, t = -2.131, P=0.038), but did not change significantly at the time of tumor recurrence (during chemotherapy without recurrence vs. after tumor recurrence, t = -0.652, P=0.632). High plasma TIMP-1 level correlated with better survival in Grade IV glioma patients (hazard ratio: 0.550, 95% CI: 0.101-1.000, P=0.036). In Grade IV gliomas, patients with higher plasma TIMP-1 had significantly longer survival time than those with lower plasma TIMP-1 level (25.23 vs. 18.95 months, log-rank P=0.045). Plasma MMP-9 did not show significant association with either the pathological grade or the prognosis of glioma patients. Conclusions: Plasma TIMP-1 is associated with the diagnosis and prognosis of glioma patients. It appears to have better usefulness for guiding clinical decision making than plasma MMP-9. Further studies in an expanded patient population are needed to better define its clinical usefulness.
- 6 July 2013
- Published by Springer Nature in Clinical & Experimental Metastasis
- Vol. 30 (8) , 1009-1018
Interleukin-6 is overexpressed and augments invasiveness of human glioma stem cells in vitro
In the present study, we carried out a series of assays to investigate the expression of interleukin-6 in glioma stem cells and its role in glioma stem cells invasion. Glioma stem cells from eight surgical glioma specimens were cultured and identified. Real-time reverse transcription polymerase chain reaction and immunoassay were used to measure and compare the expression levels of interleukin-6 in glioma stem cells and matched primary glioma cells. Subsequently, neutralizing antibody against interleukin-6 or exogenous interleukin-6 was used in a Matrigel-invasion assay and effects of interleukin-6 on glioma stem cells invasiveness was then determined. The results revealed that interleukin-6 mRNA and protein expression levels were significantly higher in glioma stem cells than in primary glioma cells from the same tumor. However, its expression levels were not apparently higher in glioma stem cells from grade IV gliomas than from grade III gliomas. In Matrigel-invasion assay, glioma stem cells invasiveness markedly decreased after interleukin-6 was blocked with neutralizing antibody, but significantly increased when exogenous interleukin-6 was added. Additionally, the similar effects of interleukin-6 were also found on primary glioma cells invasiveness. Our results suggest that glioma stem cells are likely to be the major tumor source of immunosuppressive cytokines interleukin-6 and thereby play a crucial role in determining glioma malignancy, immunosuppression and immune evasion. Furthermore, interleukin-6 can significantly augment glioma stem cells invasiveness in vitro, suggesting a potential target in future therapy for glioma stem cells rather than for their derivatives.
- 6 July 2013
- Published by Springer Nature in Clinical & Experimental Metastasis
- Vol. 30 (8) , 1009-1018
Interleukin-6 is overexpressed and augments invasiveness of human glioma stem cells in vitro
In the present study, we carried out a series of assays to investigate the expression of interleukin-6 in glioma stem cells and its role in glioma stem cells invasion. Glioma stem cells from eight surgical glioma specimens were cultured and identified. Real-time reverse transcription polymerase chain reaction and immunoassay were used to measure and compare the expression levels of interleukin-6 in glioma stem cells and matched primary glioma cells. Subsequently, neutralizing antibody against interleukin-6 or exogenous interleukin-6 was used in a Matrigel-invasion assay and effects of interleukin-6 on glioma stem cells invasiveness was then determined. The results revealed that interleukin-6 mRNA and protein expression levels were significantly higher in glioma stem cells than in primary glioma cells from the same tumor. However, its expression levels were not apparently higher in glioma stem cells from grade IV gliomas than from grade III gliomas. In Matrigel-invasion assay, glioma stem cells invasiveness markedly decreased after interleukin-6 was blocked with neutralizing antibody, but significantly increased when exogenous interleukin-6 was added. Additionally, the similar effects of interleukin-6 were also found on primary glioma cells invasiveness. Our results suggest that glioma stem cells are likely to be the major tumor source of immunosuppressive cytokines interleukin-6 and thereby play a crucial role in determining glioma malignancy, immunosuppression and immune evasion. Furthermore, interleukin-6 can significantly augment glioma stem cells invasiveness in vitro, suggesting a potential target in future therapy for glioma stem cells rather than for their derivatives.
- Open Access
- 1 January 2013
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 11 (1) , 269
Microsurgical management of giant malignant peripheral nerve sheath tumor of the scalp: two case reports and a literature review
Malignant peripheral nerve sheath tumors of the scalp are rare lesions of the nervous system. Only 14 cases have been reported to date. The field of neurosurgery has struggled with diagnosing and treating these tumors. In this report, we present two cases of giant malignant peripheral nerve sheath tumors of the scalp and retrospectively analyze the clinical features, imaging findings, pathological features, and prognoses of these two patients. Each underwent microsurgery and radiotherapy. In addition, based on a literature review, we discuss the diagnostic and therapeutic strategies used to treat these unusual lesions.
- 1 January 2013
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 11 (1) , 269
Open AccessMicrosurgical management of giant malignant peripheral nerve sheath tumor of the scalp: two case reports and a literature review
Malignant peripheral nerve sheath tumors of the scalp are rare lesions of the nervous system. Only 14 cases have been reported to date. The field of neurosurgery has struggled with diagnosing and treating these tumors. In this report, we present two cases of giant malignant peripheral nerve sheath tumors of the scalp and retrospectively analyze the clinical features, imaging findings, pathological features, and prognoses of these two patients. Each underwent microsurgery and radiotherapy. In addition, based on a literature review, we discuss the diagnostic and therapeutic strategies used to treat these unusual lesions.
- Open Access
- 4 May 2012
- Published by Spandidos Publications in Oncology Reports
- Vol. 28 (1) , 155-160
Expression and correlation of Bcl-2 with pathological grades in human glioma stem cells
The anti-apoptotic gene, B-cell lymphoma-2 (Bcl-2), has been reported to be overexpressed in gliomas and is related to tumor prognosis, suggesting a potential therapeutic target. Additionally, recent studies have demonstrated the existence of brain glioma stem cells (BGSCs) which are tumorigenic, self-renewable and dominate the biological behavior of gliomas. Currently BGSCs are committed as a new target of glioma therapies. However, few studies have focused on the expression of Bcl-2 in BGSCs. We performed a series of experiments to culture BGSCs from eight clinical specimens, followed by real-time RT-PCR and immunoassays to compare the expression levels of Bcl-2 in BGSCs and their corresponding primary glioma cells (PGCs). The results showed that Bcl-2 mRNA and protein expression levels are higher in BGSCs compared to their counterparts, and the expression levels are related to glioma malignancies. As an anti-apoptotic gene, Bcl-2 assigns immortality characteristics to cells, which coincide with the pivotal biological feature of BGSCs. The experimental results indicated that BGSCs would evade apoptosis for higher Bcl-2 expression, and may interpret the drug resistance of glioma to cytotoxic drugs and other pro-apoptotic agents. New therapies targeting Bcl-2 must induce apoptosis in BGSCs, thus, resulting in treatment or even eradication of glioma.
- 4 May 2012
- Published by Spandidos Publications in Oncology Reports
- Vol. 28 (1) , 155-160
Open AccessExpression and correlation of Bcl-2 with pathological grades in human glioma stem cells
The anti-apoptotic gene, B-cell lymphoma-2 (Bcl-2), has been reported to be overexpressed in gliomas and is related to tumor prognosis, suggesting a potential therapeutic target. Additionally, recent studies have demonstrated the existence of brain glioma stem cells (BGSCs) which are tumorigenic, self-renewable and dominate the biological behavior of gliomas. Currently BGSCs are committed as a new target of glioma therapies. However, few studies have focused on the expression of Bcl-2 in BGSCs. We performed a series of experiments to culture BGSCs from eight clinical specimens, followed by real-time RT-PCR and immunoassays to compare the expression levels of Bcl-2 in BGSCs and their corresponding primary glioma cells (PGCs). The results showed that Bcl-2 mRNA and protein expression levels are higher in BGSCs compared to their counterparts, and the expression levels are related to glioma malignancies. As an anti-apoptotic gene, Bcl-2 assigns immortality characteristics to cells, which coincide with the pivotal biological feature of BGSCs. The experimental results indicated that BGSCs would evade apoptosis for higher Bcl-2 expression, and may interpret the drug resistance of glioma to cytotoxic drugs and other pro-apoptotic agents. New therapies targeting Bcl-2 must induce apoptosis in BGSCs, thus, resulting in treatment or even eradication of glioma.
- 16 November 2011
- Published by SAGE Publications in Journal of Child Neurology
- Vol. 27 (6) , 767-778
Multifocal Intraparenchymal Langerhans’ Cell Histiocytosis Concomitant With an Arachnoid Cyst in a Child
Langerhans’ cell histiocytosis is a disease usually found in children and characterized by idiopathic proliferation of histiocytes in the reticuloendothelial system. Intracranial Langerhans’ cell histiocytosis presenting as multifocal intraparenchymal lesions is very rare. In this article, the authors report on a 4-year-old boy diagnosed with multifocal intraparenchymal Langerhans’ cell histiocytosis concomitant with an arachnoid cyst. After a series of laboratory examinations, the right frontal mass was surgically excised. Histological examinations confirmed the diagnosis of intracranial Langerhans’ cell histiocytosis. The patient’s intracranial hypertension symptoms were alleviated, and the remaining foci were treated by Langerhans’ cell histiocytosis–directed standard chemotherapy. At the 8-month follow-up visit, no recurrence of the excised lesion was found, and no change in the size of other lesions was seen. Supratentorial intracerebral lesions with mass effect and enhancement have rarely been described; in this report, the histological features of and therapeutic options for such a case are discussed.
- 16 November 2011
- Published by SAGE Publications in Journal of Child Neurology
- Vol. 27 (6) , 767-778
Multifocal Intraparenchymal Langerhans’ Cell Histiocytosis Concomitant With an Arachnoid Cyst in a Child
Langerhans’ cell histiocytosis is a disease usually found in children and characterized by idiopathic proliferation of histiocytes in the reticuloendothelial system. Intracranial Langerhans’ cell histiocytosis presenting as multifocal intraparenchymal lesions is very rare. In this article, the authors report on a 4-year-old boy diagnosed with multifocal intraparenchymal Langerhans’ cell histiocytosis concomitant with an arachnoid cyst. After a series of laboratory examinations, the right frontal mass was surgically excised. Histological examinations confirmed the diagnosis of intracranial Langerhans’ cell histiocytosis. The patient’s intracranial hypertension symptoms were alleviated, and the remaining foci were treated by Langerhans’ cell histiocytosis–directed standard chemotherapy. At the 8-month follow-up visit, no recurrence of the excised lesion was found, and no change in the size of other lesions was seen. Supratentorial intracerebral lesions with mass effect and enhancement have rarely been described; in this report, the histological features of and therapeutic options for such a case are discussed.
- 1 June 2011
- Published by Elsevier in Journal of Clinical Neuroscience
- Vol. 18 (6) , 821-826
Increased transforming growth factor-β2 in epidermal growth factor receptor variant III-positive glioblastoma
- 1 June 2011
- Published by Elsevier in Journal of Clinical Neuroscience
- Vol. 18 (6) , 821-826
Increased transforming growth factor-β2 in epidermal growth factor receptor variant III-positive glioblastoma